Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction - PACE-CME

Reduced Lpa with PCSK inhibitors in individuals with high Lpa at baseline contributes to CV risk reduction

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Positive phase II trial data with novel anti-PCSK9 agent
Positive phase II trial data with novel anti-PCSK9 agent
EAS 2019
Positive phase II trial data with novel anti-PCSK9 agent
- Evan Stein, MD, PhD
Effect of IL-1β inhibition on lung cancer sheds new light on the role of inflammation
Effect of IL-1β inhibition on lung cancer sheds new light on the role of inflammation
EAS 2019
Effect of IL-1β inhibition on lung cancer sheds new light on the role of inflammation
- Paul Ridker, MD
Genetic variants and elevated risk of CAD
Genetic variants and elevated risk of CAD
EAS 2019
Genetic variants and elevated risk of CAD
- Heribert Schunkert, MD
More intelligent intervention through more strategic use of CV biomarkers
More intelligent intervention through more strategic use of CV biomarkers
EAS 2019
More intelligent intervention through more strategic use of CV biomarkers